The Medicines Company (MDCO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
72
About the Report
About the Report
Summary
The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company's product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle-free patient-controlled system for short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. Its pipeline products include an investigational anesthetic agent; and an investigational lipid-lowering drug. TMC also provides acute care generic pharmaceuticals products. The company offers its products for major therapeutic areas, which include surgery and perioperative care, acute care, and cardiovascular care. It has offices and other facilities in the US, the UK, Canada and other European countries. TMC is headquartered in Parsippany, New Jersey, the US.
The Medicines Company (MDCO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
The Medicines Company, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10
The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
The Medicines Company, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13
Venture Financing 14
Annovation BioPharma Raises USD 8 Million In Series A Financing 14
Annovation BioPharma Raises USD 2 Million In Venture Financing 15
Partnerships 16
The Medicines Company Enters into Agreement with BARDA 16
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17
Licensing Agreements 18
Medicines Company Enters into Licensing Agreement with SciClone 18
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24
Equity Offering 25
The Medicines Company Completes Public Offering Of Shares For USD 201.3 Million 25
Debt Offering 26
The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26
Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28
The Medicines Company Completes Private Placement Of Notes For USD 275 Million 29
Asset Transactions 30
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34
Acquisition 36
Medicines Company Acquires Annovation Biopharma 36
Medicines Company Acquires Rempex Pharma For USD 474 Million 37
Medicines Company Completes Acquisition Of ProFibrix For Up To USD 240 Million 39
Medicines Company Completes Acquisition Of Incline Therapeutics For USD 185 Million 41
The Medicines Company-Key Competitors 43
The Medicines Company-Key Employees 44
The Medicines Company-Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 47
Financial Announcements 47
Aug 01, 2018: The Medicines Company Reports Second-Quarter 2018 Results 47
Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results 49
Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results 51
Oct 25, 2017: The Medicines Company Reports Third-Quarter 2017 Business and Financial Results 53
Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 55
Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results 57
Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results 58
Corporate Communications 60
Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition 60
Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors 61
Nov 15, 2017: The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors 62
Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors 63
Clinical Trials 64
Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran 64
Mar 17, 2017: The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran 66
Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17 68
Jan 25, 2017: The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology's 66th Annual Scientific Session 69
Jan 08, 2017: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran 70
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
List of Figure
List of Figures
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
The Medicines Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10
The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13
Annovation BioPharma Raises USD 8 Million In Series A Financing 14
Annovation BioPharma Raises USD 2 Million In Venture Financing 15
The Medicines Company Enters into Agreement with BARDA 16
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17
Medicines Company Enters into Licensing Agreement with SciClone 18
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 20
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 22
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 24
The Medicines Company Completes Public Offering Of Shares For USD 201.3 Million 25
The Medicines Company Raises USD402.5 Million in Private Placement of 2.75% Notes Due 2023 26
Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 28
The Medicines Company Completes Private Placement Of Notes For USD 275 Million 29
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 30
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 32
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 34
Medicines Company Acquires Annovation Biopharma 36
Medicines Company Acquires Rempex Pharma For USD 474 Million 37
Medicines Company Completes Acquisition Of ProFibrix For Up To USD 240 Million 39
Medicines Company Completes Acquisition Of Incline Therapeutics For USD 185 Million 41
The Medicines Company, Key Competitors 43
The Medicines Company, Key Employees 44
The Medicines Company, Subsidiaries 45
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.